internal
Albert Bourla
Chairman and Chief Executive Officer
Executive
6 yr
5 reports
Pfizer Inc. ·PFE
Unified R&D led by a single scientific president
Pharmaceuticals · Fortune #65 · Divisional structure · 88K employees · New York, NY
View as of:
5
CEO span
↓ tighter than peers (avg 7)
1
Avg span
tight
2
Max depth
2 levels
3 yr
Avg tenure
↓ 1.0yr from FY2024
60%
Internal hires
↑ above industry avg
Consolidated financials FY2023 · period end 2023-12-31 · 10-K
Revenue
$50.9B
Net income
$7.8B
Total assets
$208.2B
Shares out
5.69B
Sourced from Pfizer Inc. DEF 14A · filed 2026-03-12 ↗ View on SEC
Interactive org chart
Pfizer Inc. organizational chart
Explore the executive structure, reporting layers, and scenario-ready operating model from public filings.
Open editable chart
Take this model into your AI workspace Use AI to reason through the model, then bring the scenario back into Creately Atlas.
Choose a prompt, then open an AI app and paste.
Download the CSV data instead
Pfizer operates a divisional pharmaceutical structure with a distinctive unified R&D model, where one Chief Scientific Officer oversees all research and development globally. This page maps the CEO’s direct reports, executive team composition, recent leadership changes, and how Pfizer compares structurally with peer biopharma companies.
What to model
Use the chart to test org decisions, not just view reporting lines
Start with the public baseline, then use the scenario views and source-backed changes to ask what happens when leadership, span, or team ownership shifts.
Latest signal Chris Boshoff joined as Chief Scientific Officer and President, Research & Development
Appointed effective January 1, 2025 to unify Pfizer’s R&D organization.
Source · See change logScenario views in the chart
- Add Chief AI Officer Create a Chief AI Officer role reporting to the CEO to centralize AI strategy across R&D, manufacturing, and commercial.
- Split R&D President Role Separate discovery and development into two presidents to reduce span and increase specialization.
Atlas work this supports
- Connect Workday or UKG Get these analytics for YOUR org — tenure, span of control, headcount, automatically from your HRIS.
- Connect Salesforce Map your target accounts like this. Import contacts, visualize decision chains, plan multi-threading.
- Plan a Reorg Use this as a starting point. Model scenarios, compare structures, present options to your board.
The people
Who's running this
6 executives identified as Named Executive Officers in the most recent SEC proxy. Bar length scales with tenure.
David Denton
Chief Financial Officer, EVP
Finance
3 yr
0 reports
internal
Chris Boshoff
Chief Scientific Officer and President, Research & Development
R&D
1 yr
0 reports
internal
Angela Malik
Chief U.S. Commercial Officer, EVP
Commercial
4 yr
0 reports
internal
Douglas Lankler
Chief Legal Officer, EVP
Legal
3 yr
0 reports
Andrew Baum
Chief Strategy and Innovation Officer, EVP
Strategy
2 yr
0 reports
The pay
Executive compensation
From the most recent DEF 14A Summary Compensation Table. 1 named executive officers disclosed. Bar length scales with total compensation.
Albert Bourla $27.6M
- Base salary
- $1.80M
- Bonus
- $9.44M
- Stock awards
- $9.00M
- Option awards
- $5.40M
- Non-equity incentive
- $4K
- Other
- $1.94M
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
The businesses
How Pfizer Inc. divides the work
3 divisions report into the group CEO. Tile size scales with estimated headcount.
Research & Development
18K employees
Chief Scientific Officer and President, R&D (Chris Boshoff)
Leads discovery, clinical development, and pipeline strategy across all therapeutic areas.
U.S. Commercial
20K employees
Chief U.S. Commercial Officer (Angela Malik)
Responsible for sales, marketing, and market access for Pfizer products in the United States.
Finance
5K employees
Chief Financial Officer (David Denton)
Oversees financial strategy, reporting, capital allocation, and investor relations.
The thesis
Why this org is unusual
Pfizer’s most distinctive structural feature is the consolidation of all global research and development under a single Chief Scientific Officer who also serves as President of R&D.
This unification, formalized in 2025, replaced a more fragmented therapeutic-area leadership model and centralizes scientific capital allocation. The CEO directly oversees commercial, finance, legal, strategy, and R&D leaders, reflecting a divisional business model with strong functional control at the top.
The structure emphasizes accountability for scientific productivity and pipeline prioritization, with R&D elevated to equal standing with commercial and financial leadership. This design supports Pfizer’s post-COVID portfolio reset, large-scale M&A integration, and renewed focus on oncology and specialty medicines.
- Single unified R&D president
- Strategy and innovation elevated to C-suite
The comparison
How Pfizer Inc. stacks up
Compared with peers such as Merck and Johnson & Johnson, Pfizer places unusually broad authority in a single R&D president rather than multiple therapeutic CEOs. Unlike Novartis, which separates innovation and development leadership, Pfizer consolidates both. The CEO’s direct span is comparable to large pharma …
C-suite size
Reporting depth
Pfizer Inc.
2 levels
4 levels
5 levels
Novartis
4 levels
4 levels
Avg C-suite tenure
Has COO / Has CAIO
Pfizer Inc. — no COO — no CAIO
Novartis — no COO ✓ CAIO
Current signals
What changed recently
The most consequential change was the 2025 appointment of Chris Boshoff as unified Chief Scientific Officer, consolidating all R&D under one leader.
- newChris Boshoff Chief Scientific Officer and President, Research & Development
Appointed effective January 1, 2025 to unify Pfizer’s R&D organization.
Source - Date not confirmed newAndrew Baum Chief Strategy and Innovation Officer
Joined Pfizer in 2024 to lead enterprise strategy and innovation portfolio.
Source
Leadership Timeline
Year-over-year executive structure based on SEC proxy and annual filings.
FY2025
DEF 14A filed 2026-03-12
- CEO
- Albert Bourla
- CEO span
- 5
- C-suite
- 5
- Avg tenure
- 3 yr
R&D unified under a single Chief Scientific Officer.
Named executive officers (5)
- Albert Bourla - Chairman and CEO since 2019
- David Denton - CFO since 2022
- Chris Boshoff - Chief Scientific Officer since 2025
- Angela Malik - Chief U.S. Commercial Officer since 2022
- Douglas Lankler - Chief Legal Officer since 2022
FY2024
DEF 14A filed 2025-03-13
- CEO
- Albert Bourla
- CEO span
- 5
- C-suite
- 5
- Avg tenure
- 4 yr
R&D leadership transitioning ahead of 2025 reorganization.
Named executive officers (4)
- Albert Bourla - Chairman and CEO since 2019
- David Denton - CFO since 2022
- Mikael Dolsten - Chief Scientific Officer since 2018
- Angela Malik - Chief U.S. Commercial Officer since 2022
Year-over-year changes
The key change was the replacement of the prior CSO with a unified R&D president model.
- CEO span: 5 → 5
- C-suite size: 5 → 5
- Avg tenure: 4 → 3 yr
- new Chris Boshoff - Chief Scientific Officer and President, R&D (was Chief Oncology Officer) (DEF 14A filed 2026-03-12)
Frequently Asked Questions
Who is the CEO of Pfizer?
Albert Bourla has served as Chairman and Chief Executive Officer of Pfizer since 2019.
What type of organizational structure does Pfizer use?
Pfizer uses a divisional pharmaceutical structure with strong functional leadership at the corporate level.
How many direct reports does Pfizer's CEO have?
Pfizer’s CEO has five direct reports, including finance, R&D, commercial, legal, and strategy leaders.
How has Pfizer's leadership changed recently?
In 2025, Pfizer unified all R&D under a single Chief Scientific Officer and added a Chief Strategy and Innovation Officer.
Who reports directly to Pfizer's CEO?
Direct reports include the CFO, Chief Scientific Officer, Chief U.S. Commercial Officer, Chief Legal Officer, and Chief Strategy and Innovation Officer.
Sources
- Pfizer Proxy Statement, Mar 2025
- SEC EDGAR: Pfizer Inc. DEF 14A Proxy Statement
- SEC EDGAR: Pfizer Inc. 10-K Annual Report
Reference
Cite this page
If you reference this page in research, analysis, or news writing, use one of the formats below. Citation includes the SEC filing source where applicable.
APA 7th
Creately. (2026). Pfizer Inc. organizational structure. Creately. Retrieved , from https://creately.com/org-chart/fortune-500/pfizer/MLA 9th
"Pfizer Inc. Organizational Structure." Creately, April 1, 2026, https://creately.com/org-chart/fortune-500/pfizer/. Accessed .Chicago 17
Creately. "Pfizer Inc. Organizational Structure." Last modified April 1, 2026. https://creately.com/org-chart/fortune-500/pfizer/.Original SEC source View on SEC ↗
Pfizer Inc.. DEF 14A. Filed 2026-03-12. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/78003/000007800326000033/pfe-20260312.htmPermanent URL: https://creately.com/org-chart/fortune-500/pfizer/ · last updated 2026-04-01